Vascular Biogenics Ltd (VBLT) Holding Reduced by Turner Investments LLC

Vascular Biogenics Ltd (VBLT) Holding Reduced by Turner Investments LLC

Turner Investments LLC cut its position in Vascular Biogenics Ltd (NASDAQ:VBLT) by 60.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 79,611 shares of the biopharmaceutical company’s stock after selling 123,850 shares during the period. Turner Investments LLC’s holdings in Vascular Biogenics were worth $438,000 as of its most recent filing with the SEC.

Separately, Menta Capital LLC raised its stake in shares of Vascular Biogenics by 46.0% in the fourth quarter. Menta Capital LLC now owns 115,735 shares of the biopharmaceutical company’s stock worth $561,000 after buying an additional 36,482 shares in the last quarter. Hedge funds and other institutional investors own 14.95% of the company’s stock.

Vascular Biogenics Ltd (NASDAQ:VBLT) traded up 1.376% during mid-day trading on Thursday, reaching $5.525. 8,853 shares of the company traded hands. The firm’s market cap is $148.66 million. Vascular Biogenics Ltd has a one year low of $3.54 and a one year high of $7.58. The stock’s 50-day moving average price is $5.71 and its 200-day moving average price is $5.40.

Vascular Biogenics (NASDAQ:VBLT) last issued its earnings results on Monday, May 15th. The biopharmaceutical company reported ($0.19) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by $0.02. Analysts forecast that Vascular Biogenics Ltd will post ($0.82) earnings per share for the current fiscal year.

Several research firms recently commented on VBLT. Piper Jaffray Companies reissued an “overweight” rating and set a $11.00 target price on shares of Vascular Biogenics in a research note on Tuesday, February 21st. Zacks Investment Research raised shares of Vascular Biogenics from a “sell” rating to a “hold” rating in a research note on Tuesday, May 16th. Finally, HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of Vascular Biogenics in a research note on Tuesday, March 28th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $12.90.

About Vascular Biogenics

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:VBLT”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding VBLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vascular Biogenics Ltd (NASDAQ:VBLT).

Related posts

Leave a Comment